On May 11, 2022 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that members of its management team will participate in two upcoming investor events (Press release, Molecular Partners, MAY 11, 2022, View Source [SID1234614232]). In addition, the Company will publish its Q1 2022 earnings report on May 12, after the close of trading at the NASDAQ exchange.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

2022 RBC Capital Markets Global Healthcare Conference, in-person, May 17-18, 2022

Fireside chat – Tuesday, May 17, 2022, at 9:00am ET

BioEquity Europe 2022 – virtual 1×1 meetings, Monday-Tuesday, May 23-24, 2022
Virtual presentation made available on-demand
Presentations will be made available through the Molecular Partners website.